NEWEST TO THE MARKET (FDA Drug Approvals)
-
Polivy (polatuzumab vedotin-piiq) – To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
Approval Date: 10 June 2019
—————————————————————————————————————————————————————————————————————————————
-
Piqray (alpelisib) – To treat breast cancer
Approval Date: 24 May 2019
—————————————————————————————————————————————————————————————————————————————
-
Vyndaqel (tafamidis meglumine) – To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.
Approval Date: 3 May 2019
—————————————————————————————————————————————————————————————————————————————
-
Skyrizi (risankizumab-rzaa) – To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Approval Date: 23 Apr 2019
—————————————————————————————————————————————————————————————————————————————
-
Balversa (erdafitinib) – To treat adult patients with locally advanced or metastatic bladder cancer.
Approval Date: 12 Apr 2019
—————————————————————————————————————————————————————————————————————————————
-
Evenity (romosozumab-aqqg) – To treat osteoporosis in postmenopausal women at high risk of fracture.
Approval Date: 9 Apr 2019
—————————————————————————————————————————————————————————————————————————————
-
Mayzent (siponimod) – To treat adults with relapsing forms of multiple sclerosis.
Approval Date: 26 Mar 2019
—————————————————————————————————————————————————————————————————————————————
-
Sunosi (solriamfetol) – To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
Approval Date: 20 Mar 2019
—————————————————————————————————————————————————————————————————————————————
-
Zulresso (brexanolone) – To treat postpartum depression (PPD) in adult women.
Approval Date: 19 Mar 2019
—————————————————————————————————————————————————————————————————————————————
-
Egaten (triclabendazole)- To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”.
Approval Date: 13 Feb 2019
—————————————————————————————————————————————————————————————————————————————
-
Cablivi (caplacizumab-yhdp) – To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Approval Date: 6 Feb 2019
—————————————————————————————————————————————————————————————————————————————
-
Jeuveau (prabotulinumtoxinA-xvfs) – For the temporary improvement in the appearance of moderate to severe glabellar lines associated with levit8ed corrugator and/or procerus muscle activity in adult patients.
Approval Date: 1 Feb 2019